Mivacurium
This short-acting neuromuscular blocking agent relaxes skeletal muscles by blocking nerve signals at the junction between nerves and muscles. It is used during surgery and procedures requiring temporary muscle paralysis and mechanical ventilation.
Peso Molecular
1029,3000 g/mol
LogP
8,70
TPSA
145,00 Ų
Regra dos 5 de Lipinski
Reprovado
Áreas Terapêuticas
Mecanismo de Ação
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
COc1cc2c(cc1OC)[C@@H](Cc1cc(OC)c(OC)c(OC)c1)[N+](C)(CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]1(C)CCc3cc(OC)c(OC)cc3[C@H]1Cc1cc(OC)c(OC)c(OC)c1)CC2
InChI
InChI=1S/C58H80N2O14/c1-59(25-21-41-35-47(63-3)49(65-5)37-43(41)45(59)29-39-31-51(67-7)57(71-11)52(32-39)68-8)23-17-27-73-55(61)19-15-13-14-16-20-56(62)74-28-18-24-60(2)26-22-42-36-48(64-4)50(66-6)38-44(42)46(60)30-40-33-53(69-9)58(72-12)54(34-40)70-10/h13-14,31-38,45-46H,15-30H2,1-12H3/q+2/b14-13+/t45-,46-,59?,60?/m1/s1
Molecular Formula
C58H80N2O14+2
HBD / HBA
- / 14
Ligações Rotacionáveis
30
Átomos Pesados
74
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
This short-acting neuromuscular blocking agent relaxes skeletal muscles by blocking nerve signals at the junction between nerves and muscles. It is used during surgery and procedures requiring temporary muscle paralysis and mechanical ventilation.
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Yes, Mivacurium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1182833. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5281042. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="mivacurium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/mivacurium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/mivacurium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/mivacurium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="mivacurium"></drugfyi-drug>